We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 82.8% of patients treated with Vtama achieved the ...
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in ...
Intertriginous plaque psoriasis, also known as inverse psoriasis, affects approximately 20%–30% of individuals who have plaque psoriasis. The treatment for plaque psoriasis in intertriginous areas is ...
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis. I think a survey like ...
The US Food and Drug Administration (FDA) has approved roflumilast 0.3% cream for the topical treatment of plaque psoriasis, "including intertriginous areas," in patients aged 12 years and older.
If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to ...
The woman had axillary granular parakeratosis (GP), a benign condition. First described in 1991, this disease presents with erythematous hyperpigmented and hyperkeratotic papules and plaques in ...
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses findings of a recent survey exploring the emotional burden of plaque psoriasis and unmet needs related to ...
Vision – To be the world's leading and most trusted provider of information and services that will make a real difference in clinical practice and improve outcomes for patients. Mission – To lead the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback